Clinical Application of Radiolabeled Human X Human Monoclonal Antibody with Interferon in the Treatment of Malignant Glioma—Preliminary Report

Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab

“…This is an interesting comment on the natural human immune response to cancer antigens [5,8]. Of particular specificity and interest was the binding of pritumumab to brain tumor tissues [17,20,26,27].…”

“…The major reason for such an aggressive and difficult to treat tumor is the rapid diffuse infiltration of individual tumor cells into the surrounding brain parenchyma, most often before diagnosis, making surgical debulking difficult. Pritumumab has been used to treat 249 brain cancer patients in various trials in Japan [29][30][31][32][33][34][35]. Most of the treated patients have been diagnosed with glioblastomas but others with astrocytomas or neuroblastomas.…”

“…Patients either in an early Phase 2 setting or a late Phase 2 setting received pritumumab as shown in Tables 5 and 6 [31,34]. Patients in a radioimmunotherapy trial received pritumumab as described [29].…”

“…From a total of 249 patients treated with pritumumab 175 were evaluated (see Tables 5 and 6; refs [29][30][31][32][33][34][35]. Of these, one group received doses under a Phase 1 setting to determine the safety of the antibody [30,33].…”

“…In a study [29], 7 patients with recurrent malignant glioma were treated with 131-I labeled pritumumab (2.5 mg, 2.5 mCi) intra-tumorally through Ommaya reservoir, a plastic container placed in the subgaleal space that is connected to the lateral ventricle by tubing. The patients were monitored with external scintigraphy.…”